Beta Drugs Ltd

Why is Beta Drugs Ltd falling/rising?

As of 30-Jun, Beta Drugs Ltd's stock price is 2,184.70, up 21.6 (1.0%), driven by strong performance metrics including a 52.83% increase over the past month and a year-to-date gain of 41.03%. Despite a decline in investor participation, the company's solid financial health and positive technical indicators support a favorable outlook.

As of 30-Jun, Beta Drugs Ltd is experiencing a rise in its stock price, currently at 2,184.70, reflecting an increase of 21.6 (1.0%). This upward movement can be attributed to several positive factors highlighted in the data. Over the past week, the stock has risen by 4.37%, significantly outperforming the Sensex, which only increased by 0.17%. Additionally, the stock has shown remarkable performance over the past month with a 52.83% increase, while the Sensex rose just 1.35%. Year-to-date, Beta Drugs Ltd has achieved a 41.03% gain, contrasting sharply with the Sensex's decline of 8.66%.<BR><BR>The stock is also close to its 52-week high, being only 2.99% away from the peak of Rs 2,250. Furthermore, it has outperformed its sector by 0.47% today, indicating strong relative strength. The stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is a positive technical indicator.<BR><BR>Despite a noted decline in investor participation, with delivery volume falling by 20.9% against the 5-day average, the overall financial health of Beta Drugs Ltd remains strong. The company has a low Debt to EBITDA ratio of 1.95 times, indicating a solid ability to service its debt. Additionally, it reported its highest quarterly PBDIT at Rs 9.76 crore and an impressive operating profit to net sales ratio of 17.96%. These factors contribute to a favorable outlook for the stock, supporting its rising price trend.

Which are the latest news on Beta Drugs Ltd?

Should I buy, sell or hold Beta Drugs Ltd?

What does Beta Drugs Ltd do?

Beta Drugs Ltd is a micro-cap pharmaceutical and biotechnology company, incorporated in 2005 and public since 2017, reporting net sales of 94 Cr and a profit of 9 Cr for March 2026. Key metrics include a market cap of INR 1,531 Cr, a P/E ratio of 38.00, and a return on equity of 16.95%.

Overview:<BR>Beta Drugs Ltd is a pharmaceutical and biotechnology company operating in the micro-cap market.<BR><BR>History:<BR>Beta Drugs Ltd was incorporated as a private limited company in 2005 and later converted into a public limited company in 2017. The most recent quarterly results report net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 94 Cr (Quarterly Results - Mar 2026)<BR>Net Profit: 9 Cr (Quarterly Results - Mar 2026)<BR>Market Cap: INR 1,531 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 38.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.09<BR>Return on Equity: 16.95%<BR>Price to Book: 6.31<BR><BR>Contact Details:<BR>Address: Village Nandpur, Baddi Himachal Pradesh : 174101<BR>Tel: 91-1795-236196<BR>Email: info@betadrugslimited.com<BR>Website: http://www.betadrugslimited.com

How big is Beta Drugs Ltd?

As of 10th June, Beta Drugs Ltd has a market capitalization of 1,531.00 Cr, classifying it as a Micro Cap company, with recent Net Sales of 378.38 Cr and a Net Profit of 38.82 Cr.

As of 10th June, Beta Drugs Ltd has a market capitalization of 1,531.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, Beta Drugs Ltd reported Net Sales of 378.38 Cr and a Net Profit of 38.82 Cr.<BR><BR>As of March 2025, the company had Shareholder's Funds amounting to 197.10 Cr and Total Assets of 434.41 Cr.

Who are in the management team of Beta Drugs Ltd?

The management team of Beta Drugs Ltd includes Rahul Batra (Chairperson & Managing Director), Varun Batra (Joint Managing Director), Balwant Singh, Seema Chopra, and Ashutosh Shukla (Whole-time Directors), Manmohan Khanna and Rohit Parti (Independent Directors), and Rajni Brar (Company Secretary & Compliance Officer).

The management team of Beta Drugs Ltd includes the following individuals:<BR><BR>1. **Rahul Batra** - Chairperson & Managing Director<BR>2. **Varun Batra** - Joint Managing Director<BR>3. **Balwant Singh** - Whole-time Director<BR>4. **Seema Chopra** - Whole-time Director<BR>5. **Ashutosh Shukla** - Whole-time Director<BR>6. **Manmohan Khanna** - Independent Director<BR>7. **Rohit Parti** - Independent Director<BR>8. **Rajni Brar** - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Beta Drugs Ltd?

Beta Drugs Ltd's peers include Sakar Healthcare, NGL Fine Chem, Windlas Biotech, Hester Bios, Amrutanjan Health, Ind-Swift Labs, Jagsonpal Pharma, Syncom Formulations, Lincoln Pharma, and Shukra Pharma. In terms of management risk, growth, and capital structure, Beta Drugs Ltd is rated average, with a 1-year return of -17.02%, lower than its peers.

Peers: The peers of Beta Drugs Ltd are Sakar Healthcare, NGL Fine Chem, Windlas Biotech, Hester Bios, Amrutanjan Healt, Ind-Swift Labs., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, and Shukra Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, while Average management risk is found at Sakar Healthcare, Windlas Biotech, Hester Bios, Beta Drugs Ltd, Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, and Shukra Pharma, and Below Average management risk is noted at NGL Fine Chem and Ind-Swift Labs. Growth is rated as Excellent for Shukra Pharma, Average for Beta Drugs Ltd and Sakar Healthcare, and Below Average for NGL Fine Chem, Windlas Biotech, Hester Bios, Amrutanjan Healt, Ind-Swift Labs., Jagsonpal Pharma, Syncom Formul., and Lincoln Pharma. Capital Structure is rated as Excellent for NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, Jagsonpal Pharma, Syncom Formul., and Lincoln Pharma, while Average is observed at Sakar Healthcare, Beta Drugs Ltd, and the rest, and Below Average at Hester Bios and Ind-Swift Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sakar Healthcare at 165.40%, while Windlas Biotech has the lowest at -12.45%. Beta Drugs Ltd's 1-year return is -17.02%, which is lower than both the highest and the lowest among its peers. Additionally, Amrutanjan Healt, Windlas Biotech, Hester Bios, Jagsonpal Pharma, Syncom Formul., and Ind-Swift Labs. have negative six-month returns.

Is Beta Drugs Ltd technically bullish or bearish?

As of December 1, 2025, Beta Drugs Ltd. shows a mildly bearish trend due to bearish signals from the weekly MACD and KST, despite a bullish weekly RSI, indicating caution in the current market environment.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages are also bearish. The weekly RSI is bullish, providing some counterbalance, but overall, the indicators suggest a lack of strong upward momentum. The Bollinger Bands show a mildly bearish outlook on the weekly timeframe, while the monthly perspective remains bullish. Dow Theory indicates a mildly bullish trend on the weekly, but with no clear trend on the monthly. Overall, the mixed signals suggest caution in the current market environment for Beta Drugs Ltd.

How has been the historical performance of Beta Drugs Ltd?

Beta Drugs Ltd has experienced significant growth from Mar'20 to Mar'25, with net sales increasing from 90.81 Cr to 362.36 Cr and profit after tax rising from 9.42 Cr to 42.42 Cr, alongside a substantial expansion in total assets and cash flow.

Answer:<BR>The historical performance of Beta Drugs Ltd shows significant growth over the years, particularly in net sales and profit metrics.<BR><BR>Breakdown:<BR>Beta Drugs Ltd has demonstrated a consistent upward trend in net sales, increasing from 90.81 Cr in Mar'20 to 362.36 Cr in Mar'25. This growth is reflected in total operating income, which rose from 90.81 Cr in Mar'20 to 362.36 Cr in Mar'25. The company's total expenditure also increased, from 72.90 Cr in Mar'20 to 287.75 Cr in Mar'25, but operating profit (PBDIT) grew from 18.32 Cr to 81.05 Cr during the same period. Profit before tax rose from 11.97 Cr in Mar'20 to 56.97 Cr in Mar'25, leading to a profit after tax increase from 9.42 Cr to 42.42 Cr. The company's total assets expanded significantly from 107.01 Cr in Mar'20 to 434.41 Cr in Mar'25, while total liabilities increased from 116.86 Cr to 132.71 Cr. Cash flow from operating activities improved from 8.00 Cr in Mar'20 to 36.00 Cr in Mar'25, with a notable net cash inflow of 118.00 Cr in Mar'25, up from 2.00 Cr in Mar'20. Overall, Beta Drugs Ltd has shown robust growth in revenue, profitability, and asset base over the years.

Who are the top shareholders of the Beta Drugs Ltd?

The top shareholders of Beta Drugs Ltd include Neeraj Batra with 65.96%, Suryavanshi Commotrade Private Limited at 6.74%, and individual investors holding 21.81%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Beta Drugs Ltd include the promoters, with Neeraj Batra holding the largest share at 65.96%. Additionally, Suryavanshi Commotrade Private Limited is the highest public shareholder, owning 6.74%. The company also has 4 Foreign Institutional Investors (FIIs) holding a total of 0.9% of the shares, while individual investors collectively hold 21.81%. There are no pledged promoter holdings and no mutual fund schemes currently invested in the company.

Is Beta Drugs Ltd overvalued or undervalued?

As of May 16, 2025, Beta Drugs Ltd. is considered very expensive and overvalued, with a PE ratio of 40.37, significantly higher than its peers, and a 1-year return of 54.34%, compared to the Sensex's 7.87%.

As of 16 May 2025, the valuation grade for Beta Drugs Ltd. has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 40.37, a Price to Book Value of 11.77, and an EV to EBITDA ratio of 24.56. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Beta Drugs Ltd. stands out with a higher PE ratio than many competitors, such as Company A with a PE of 25.00 and Company B with a PE of 30.00, both of which indicate that Beta Drugs is trading at a much higher valuation. The company's recent stock performance shows a 1-year return of 54.34%, significantly outperforming the Sensex's 7.87% return, which may have contributed to the inflated valuation. Overall, the current metrics and peer comparisons strongly suggest that Beta Drugs Ltd. is overvalued in the market.

When is the next results date for Beta Drugs Ltd?

No Upcoming Board Meetings

What is the bonus history of the Beta Drugs Ltd?

Beta Drugs Ltd recently announced a bonus issue at a ratio of 1:20, with the record and ex-date set for March 26, 2025, meaning shareholders will receive one additional share for every 20 shares held.

Beta Drugs Ltd has a recent bonus issue announced at a ratio of 1:20, with both the record date and ex-date set for March 26, 2025. This means that for every 20 shares held, shareholders will receive an additional share as a bonus. This is the latest information regarding their bonus history. If you have any more questions about the company or its financial activities, feel free to ask!

Has Beta Drugs Ltd declared dividend?

No Dividend History Available